Get 50% OFF This Summer!

Advertisement
logo

Mankind Pharma

MANKIND
Large Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Mankind Pharma Share price and Fundamental Analysis

View All Details
View All Details
Mankind Pharma Ltd. was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.
Company Incorporation1991
ChairmanRAMESH CHAND JUNEJA
Head QuartersNew Delhi
Previous NameNA

Key Metrics

Market Cap (Cr)
1,00,425
PE Ratio
49.19
Industry P/E
39
PEG Ratio
3.33
ROE
20.02%
ROCE
24.27%
ROA
14.75%
Total Debt (Cr)
482.05
Debt to Equity
0.05
Dividend Yield
0%
EPS
49.48
Book Value & P/B
328.78 x 7.4
Face Value
1
Outstanding Shares(Cr)
41.26
Current Ratio
3.5
EV to Sales
8.57

Included In

+More

Stock Returns

1 Week+2.25%
1 Month+5.43%
6 Months-7.83%
1 Year+9.06%
3 Years+71.52%
5 Years+71.52%

CAGR

1 Year CAGR

Revenue Growth

+18.12%

Net Profit Growth

+48.26%

Operating Profit Growth

+38.77%

Dividend Growth

N/A

Stock Returns CAGR

+9.06%
no_data

No Stocks

Smart Score

2.8
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 72.70%

FIIs : 12.92%

DIIs : 11.48%

Public : 2.90%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
DII Shareholding Increased by 0.42% to 11.48% in March 2025 Qtr
FII Shareholding Decreased by 0.42% to 12.92% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Mankind Pharma Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Mankind Pharma Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Mankind Pharma Ltd. was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.

The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind' tablets and Glimestar' tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops' and Tobastar Eye Drops'. In 2007, the Company entered the consumer healthcare segment with the launch of Manforce' brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories. It entered into the business of animal healthcare segment and launched Bandykind' and Ceftiforce'. It established their Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh in year 2009.

It launched the brand, Preganews' into the consumer healthcare segment in year, 2010. In 2012, it set up their first R&D centre at IMT Manesar, in Haryana. Thereafter, in year 2014, the Company acquired Shree Jee Laboratory Private Limited along with its API manufacturing site at Behror, Rajasthan. It set up the Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh.

In 2015, subsidiaries like Lifestar Pharma LLC in the US and Mankind Pharma Pte. Limited in Singapore were formed into with the Company.

In 2017, a new manufacturing facility got established in Sikkim.

In 2019, the Company entered into female infertility business segment and launched Dydroboon' tablets.

In 2020, a subsidiary, Lifestar Pharmaceuticals Private Limited was formed in Nepal. The Company introduced a specialty therapeutic division for cardiovascular diseases (CVD) drugs segment and launched Cilaheart' tablets and Statpure' tablets in the market. It launched Zukanorm' tablets for diabetes pharmaceuticals segment.

Another new subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE got incorporated during the year 2021. It launched Mlife' tablets in the specialty division for therapeutic respiratory pharmaceuticals. It entered into specialty therapeutic neuro/central nervous system pharmaceuticals segment business with the launch of Trugaba-NT' tablets and Prebris-MNT' tablets.

In 2022, the Company acquired formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited. Further, it entered into the transplant segment with the launch of Pangraf Capsules' and Mycept' tablets. It entered into the business of oncology segment with the launch of injection Pacliall'. It acquired Daffy' and Combihale' brands from Dr. Reddy's Laboratories.

The Company operate 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022. Their formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022.

The Company is planning to raise capital from Public by issuing 40,058,844 Equity Shares through Offer for Sale.

Mankind Pharma Share Price

Mankind Pharma share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Mankind Pharma Market Cap

Market capitalization of Mankind Pharma indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Mankind Pharma is valued compared to its competitors.

Mankind Pharma PE Ratio

Mankind Pharma PE ratio helps investors understand what is the market value of each stock compared to Mankind Pharma 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Mankind Pharma PEG Ratio

The PEG ratio of Mankind Pharma evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Mankind Pharma ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Mankind Pharma generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Mankind Pharma ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Mankind Pharma in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Mankind Pharma Total Debt

Total debt of Mankind Pharma shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Mankind Pharma Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Mankind Pharma compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Mankind Pharma CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Mankind Pharma over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Mankind Pharma Technical Analysis

Technical analysis of Mankind Pharma helps investors get an insight into when they can enter or exit the stock. Key components of Mankind Pharma Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Mankind Pharma shares often struggle to rise above due to selling pressure.

Mankind Pharma Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Mankind Pharma ’s financial health and profitability.

Mankind Pharma Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Mankind Pharma Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Mankind Pharma Financials

The financials of Mankind Pharma provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Mankind Pharma Profit and Loss Statements

The profit and loss statement of Mankind Pharma highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Mankind Pharma .

Mankind Pharma Balance Sheet

The balance sheet presents a snapshot of Mankind Pharma ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Mankind Pharma Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App